Adverse Effects of Oral Progesterone
Oral progesterone is generally well-tolerated but can cause common side effects including drowsiness, dizziness, mood changes, bloating, and fluid retention, with more serious but rare risks of thromboembolism that vary significantly by formulation type. 1
Common Side Effects
The most frequently reported adverse effects with oral progesterone include:
Neurological symptoms: Drowsiness, dizziness, and fatigue are particularly common, especially with initial therapy 2, 3. Some women experience extreme dizziness and/or drowsiness that may include blurred vision, difficulty speaking, difficulty walking, and feeling abnormal 2. These effects are dose-dependent and most pronounced at higher doses (≥1200 mg) 3.
Premenstrual-like symptoms: Mood swings, bloating, fluid retention, and sleep disturbance occur frequently 1. The severity varies considerably with the specific progestational agent used 1.
Gastrointestinal effects: Nausea, vomiting, and abdominal cramping are reported 2.
Other common effects: Headaches, breast pain, irregular vaginal bleeding or spotting, hair loss, and vaginal yeast infections 2.
Formulation-Specific Differences
The type of progesterone formulation significantly impacts the side effect profile. Synthetic progestins (like medroxyprogesterone acetate) produce more significant adverse effects including dysphoria, lipid alterations, and increased androgenicity compared to natural or micronized progesterone 4. Micronized natural progesterone has better bioavailability and milder adverse effects than synthetic formulations 4.
Cardiovascular and Thrombotic Risks
The thrombotic risk profile differs substantially between progesterone formulations:
Progestin-only contraception: Initial epidemiological data on microdose progestin-based oral contraceptives (desogestrel, levonorgestrel) show no significant increase in venous thromboembolism risk relative to non-users 5. The overall meta-analysis risk was OR 1.45 (95% CI: 0.92-2.26), which was not statistically significant 5.
Medroxyprogesterone acetate caution: Two studies suggest potential increased venous thrombosis risk with high-dose medroxyprogesterone acetate, with one showing a significant increase 5. This may be explained by its pharmacological properties at high doses.
Micronized progesterone safety: Natural micronized progesterone demonstrates one of the best safety profiles in terms of thrombotic risk 6 and has a neutral or beneficial effect on blood pressure 6.
Combined therapy considerations: When used with estrogen, micronized progesterone minimizes hormonal-related cardiovascular risks compared to synthetic progestogens 6. Recent real-world evidence shows significantly lower major adverse cardiovascular events (MACE) with estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone (IRR 0.28,95% CI 0.17-0.45) 7.
Metabolic Effects
Different progestational compounds show varying effects on:
- Lipid profiles: Significant differences exist between formulations 1
- Insulin sensitivity and glucose tolerance: Potential concerns exist, particularly with first-trimester use where micronized progesterone therapy may increase risk of abnormal glucose tolerance (4.5-fold increased risk of abnormal fasting glucose, 9.4-fold for abnormal oral glucose load) 8
- Blood pressure: Natural micronized progesterone shows neutral or beneficial effects, while synthetic progestins may negatively impact blood pressure 6
- Fluid retention: Variable effects depending on antimineralocorticoid activity 1
Serious but Rare Risks
The FDA label identifies serious adverse effects requiring immediate medical attention 2:
- Abnormal blood clotting (stroke, heart attack, pulmonary embolus)
- Visual loss or blindness
- Severe headaches
- Severe chest or leg pain
Risk to fetus: Cases of congenital anomalies including cleft palate, cleft lip, hypospadias, and cardiac defects have been reported 2.
Clinical Implications
Switching between progestational agents may decrease symptoms when side effects are problematic 1. For women experiencing unacceptable side effects from all oral progestagens, transdermal patches or transvaginal administration may provide adequate endometrial management with fewer systemic side effects 1.
The timing of administration matters: progesterone capsules should be taken at bedtime to minimize the impact of drowsiness and dizziness 2. Caution is advised when driving or operating machinery, particularly during initial therapy 2.
For women with cardiovascular risk factors, micronized natural progesterone appears to be the safest option among progestational agents, with minimal impact on hemostatic parameters and favorable metabolic effects 5, 6, 4.